Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus best supportive care versus best supportive care alone in advanced EGFR-positive metastatic colorectal cancer
ACTRN12606000112561Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2003
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Cetuximab + best supportive care with Best supportive care alone (2 arms). Primary endpoint: Overall survival. Started Nov 2003; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12606000112561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000112561.